The Japanese pharma company, Takeda Pharmaceuticals has entered into strategic partnership with a 28-year-old neuroscience focused biopharmaceutical company, Neurocrine Biosciences. Established in San Diego, Neurocrine Bioscience has a diverse portfolio of therapies associated with nervous and endocrine disorders. Their offering also includes USFDA approved drugs for tardive dyskinesia, which occurs as a side effect to antipsychotic medicines.
Based on the partnership, Takeda has the license for seven pipeline programs, including three clinical stage assets for Anhedonia, treatment resistant depression and schizophrenia.
|TAK-831||Indicated for the treatment of schizophrenia acts by blocking D-amino acid oxidase pathway|
|TAK-653||AMPA potentiator indicated for the management of treatment resistant depression|
|TAK-041||GPCR agonist for treating anhedonia|
Under the terms of agreement, Takeda will be receiving USD 120 million as upfront cash and USD 495 million as development milestones. Takeda will also receive double digit royalty on net sales and can opt in or out of a 50-50 profit sharing arrangement, given they are not responsible for receiving development or commercialization milestones. Neurocrine Biosciences will be responsible for development and commercialization of all the products.